Alcon is a leader in addressing visual impairment

2 min read 28 Jul 21

Alcon makes eye care products that prevent and treat ocular conditions. Its solutions help address a range of vision impairments, including retinal disorders, refractive errors and glaucoma, that can reduce quality of life and threaten vision. The Swiss-US company is the largest maker of implantable intraocular lenses used in surgery to treat cataracts – the leading cause of blindness globally.

Why do we invest?

The global population is becoming older and more short-sighted, driving long-term demand for eye care and treatment of vision issues. Alcon boasts leading positions in both the surgical market – making equipment and consumable products involved in surgery – and the consumer eye care market, including disposable contact lenses and over-the-counter eye products like eye drops. We believe its large share of a growing market is supported by product quality and patent protection, driven by strong research and development spending that spurs innovation.

What is their impact?

Alcon is a leader in addressing ocular health problems. Its products enhance people’s quality of life by preventing and treating eye conditions and helping them see clearly. Good vision helps people to work productively, enjoy life independently, and to maintain social contact, especially in old age. Yet almost 200 million people worldwide suffer vision impairments that could be addressed by Alcon’s products.

By preventing and treating non-communicable eye disease, Alcon contributes to the achievement of UN Sustainable Development Goal 3 – ensuring healthy lives and promoting well-being for all at all ages.

7 million

Cataract surgeries enabled globally each year by Alcon’s implantable intraocular lenses.*

 

The views expressed here should not be taken as a recommendation, advice or forecast.

The value and income from any fund's assets will go down as well as up. This will cause the value of your investment to fall as well as rise. There is no guarantee that any fund will achieve its objective and you may get back less than you originally invested. 

While we support the UN SDGs, we are not associated with the UN and our funds are not endorsed by them.

* Source: M&G estimates based on Alcon data

Related insights